Liangfang Zhang

Molecular Biology · 2007–2022

A researcher in the Science corpus: 17 papers; trusts 5 researchers and is trusted by 1 researcher here, as inferred from the citation graph.

Subfields

• Molecular Biology — 82 citations into it; #17,218 of 17,773 by trust here, #3,922 by citations
• Biomedical Engineering — 76 citations into it
• Biomaterials — 69 citations into it; #2,097 of 2,152 by trust here, #528 by citations
• Oncology — 17 citations into it

Whom Liangfang Zhang trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. O. Farokhzad
2. Vladimir Torchilin
3. F. Gu
4. L. Zhang
5. Mauro Ferrari
6. R. Müller
7. Robert Langer
8. Colin W. Pouton
9. Huan Meng
10. Mark E. Davis

Who trusts Liangfang Zhang overall

1. Phatsapong Yingchoncharoen
2. D. Kalinowski
3. M. Yu
4. Carlotta Pucci
5. Young-Eun Choi

Papers from Liangfang Zhang's perspective

Ordered by how strongly the researchers Liangfang Zhang trusts endorse each paper. Same corpus, a different order for every researcher.

1. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. (Proceedings of the National Academy of Sciences of the United States of America)
2. Recent advances with liposomes as pharmaceutical carriers (Nature reviews. Drug discovery)
3. Polymer conjugates as anticancer nanomedicines (Nature Reviews. Cancer)
4. Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies (Clinical Cancer Research)
5. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. (Progress in lipid research)
6. Effect of pegylation on pharmaceuticals (Nature reviews. Drug discovery)
7. Mechanisms of cancer drug resistance. (Annual Review of Medicine)
8. Nanoparticles in Medicine: Therapeutic Applications and Developments (Clinical pharmacology and therapy)
9. Micellar Nanocarriers: Pharmaceutical Perspectives (Pharmaceutical Research)
10. Nanoparticle therapeutics: an emerging treatment modality for cancer (Nature reviews. Drug discovery)

Their papers

• Monitoring of the central blood pressure waveform via a conformal ultrasonic device (2018) — 779 citations
• Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers (2008) — 715 citations
• Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. (2007) — 916 citations
• Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform (2011) — 2,150 citations
• PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. (2009) — 683 citations
• Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform. (2008) — 969 citations
• Micro/Nanorobots for Biomedicine: Delivery, Surgery, Sensing, and Detoxification (2017) — 1,339 citations
• Nanoparticle biointerfacing via platelet membrane cloaking (2015) — 1,579 citations
• Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. (2012) — 638 citations
• Targeting drugs to tumours using cell membrane-coated nanoparticles (2022) — 821 citations
• Enzyme-powered Janus platelet cell robots for active and targeted drug delivery (2020) — 330 citations
• Cell Membrane Coating Nanotechnology (2018) — 1,516 citations
• Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis (2018) — 830 citations
• Erythrocyte–Platelet Hybrid Membrane Coating for Enhanced Nanoparticle Functionalization (2017) — 649 citations
• Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery (2014) — 1,286 citations
• A biomimetic nanosponge that absorbs pore-forming toxins (2013) — 660 citations
• Development of nanoparticles for antimicrobial drug delivery. (2010) — 860 citations